TXG furnishes Item 2.02 8-K with Q3 2025 results (Ex. 99.1)
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
10x Genomics (TXG) furnished an 8-K announcing quarterly results. The company reported that it issued a press release with financial results for the quarter ended September 30, 2025, and attached it as Exhibit 99.1. The disclosure under Item 2.02 is furnished and not deemed filed under Section 18 of the Exchange Act.
10x Genomics’ Class A common stock trades on Nasdaq under the symbol TXG. The exhibit list includes the press release dated November 6, 2025 and the Inline XBRL cover page file.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
______________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 6, 2025
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(925 ) 401-7300
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
___________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 6, 2025, 10x Genomics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.
The information furnished pursuant to Item 2.02 in this Current Report on Form 8-K and the press release attached as Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits.
Exhibit No. | Description of Exhibits | ||||||||||
| 99.1 | Press Release dated November 6, 2025. | ||||||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | ||||||||||
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
10x Genomics, Inc. | ||||||||
By: | /s/ Eric S. Whitaker | |||||||
Name: | Eric S. Whitaker | |||||||
Title: | Chief Legal Officer | |||||||
| Date: November 6, 2025 | ||||||||
FAQ
What did 10x Genomics (TXG) announce in this 8-K?
The company furnished a press release announcing its financial results for the quarter ended September 30, 2025.
Which period do the results cover for TXG?
The results cover the quarter ended September 30, 2025.
How were the results provided to investors?
Through a press release attached as Exhibit 99.1 to the 8-K.
Is the information considered filed or furnished?
It is furnished under Item 2.02 and not deemed filed under Section 18 of the Exchange Act.
What exhibits are included with the TXG 8-K?
Exhibit 99.1: Press Release dated November 6, 2025; Exhibit 104: Cover Page Interactive Data File (Inline XBRL).
What is 10x Genomics’ trading symbol and exchange?
TXG on The Nasdaq Stock Market LLC.